BioPharmSignal logoBioPharmSignal

Biotech News

Allogene Highlights Clinical Progress and Next-Generation Innovation Across Its Off-the-Shelf CAR T Platform at SITC Annual Meeting

Allogene Therapeutics (ALLO)Allogene TherapeuticsConference / presentation

Two Invited Presentations Showcase Clinical Progress in Solid Tumors and Allogene's Broader Vision in Oncology and Autoimmune Disease Preclinical Poster Features Next-Generation DLL3/CD70 Dual CAR T Product Candidate for Small Cell Lung Cancer and Other Neuroendocrine Tumors, Demonstrating

Related news

ALLOAllogene Therapeutics2026-08-31 12:30 EST

Allogene Therapeutics Announces Participation in September Investor Conference

ALLOAllogene Therapeutics2026-04-15 12:30 EST

Allogene Therapeutics Announces Nature Communications Publication Highlighting Pre-Clinical Data for ALLO-329, a Next Generation Dual-Targeted CD19/CD70 Allogeneic CAR T for Autoimmune Diseases

LEGNLegend Biotech Corporation2026-01-12 13:00 EST

Legend Biotech Highlights Recent Business Updates at 44th Annual J.P. Morgan Healthcare Conference

LEGNLegend Biotech Corporation2026-01-21 13:00 EST

Legend Biotech to Present CARVYKTI® Data at 2026 Tandem Meetings Reinforcing Growing Evidence Supporting Earlier Use

View all latest news

Allogene Therapeutics

Allogeneic CAR T Company Allogene Therapeutics develops off-the-shelf CAR T-cell therapies for cancer and autoimmune disease. Its platform is intended to provide readily available treatment without patient-specific cell collection and manufacturing. Cema-Cel Cemacabtagene ansegedleucel, or cema-cel, is a CD19-directed AlloCAR T candidate...

Recent company news

ALLOAllogene Therapeutics2026-11-05 21:02 EST

Allogene Therapeutics Reports Third Quarter 2026 Financial Results and Business Update

ALLOAllogene Therapeutics2026-11-03 13:00 EST

Allogene Highlights Clinical Progress and Next-Generation Innovation Across Its Off-the-Shelf CAR T Platform at SITC Annual Meeting

ALLOAllogene Therapeutics2026-10-29 12:30 EST

Allogene Therapeutics Announces November Investor Events Highlighting Q3 Results and Initial ALLO-329 Autoimmune Clinical Data

ALLOAllogene Therapeutics2026-10-26 12:30 EST

Allogene Therapeutics Announces Participation in Upcoming Investor Conferences

ALLOAllogene Therapeutics2026-09-02 12:30 EST

Allogene Therapeutics Announces Retirement of Chief Financial Officer Geoffrey Parker

Stock data

Close
1.09 USD
Market cap
707.57M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States